NZ515997A - Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof - Google Patents

Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof

Info

Publication number
NZ515997A
NZ515997A NZ515997A NZ51599700A NZ515997A NZ 515997 A NZ515997 A NZ 515997A NZ 515997 A NZ515997 A NZ 515997A NZ 51599700 A NZ51599700 A NZ 51599700A NZ 515997 A NZ515997 A NZ 515997A
Authority
NZ
New Zealand
Prior art keywords
short acting
release
acting hypnotic
salt
minutes
Prior art date
Application number
NZ515997A
Other languages
English (en)
Inventor
Gerard Alaux
Frederic Andre
Jean Ducassou
Gareth Lewis
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8242028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ515997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NZ515997A publication Critical patent/NZ515997A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ515997A 1999-06-28 2000-06-27 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof NZ515997A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99401605A EP1064937A1 (en) 1999-06-28 1999-06-28 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
PCT/EP2000/006792 WO2001000181A2 (en) 1999-06-28 2000-06-27 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof

Publications (1)

Publication Number Publication Date
NZ515997A true NZ515997A (en) 2004-03-26

Family

ID=8242028

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515997A NZ515997A (en) 1999-06-28 2000-06-27 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof

Country Status (28)

Country Link
EP (2) EP1064937A1 (https=)
JP (1) JP2003503340A (https=)
KR (1) KR20020015064A (https=)
CN (1) CN100415216C (https=)
AR (1) AR024491A1 (https=)
AT (1) ATE269062T1 (https=)
AU (1) AU782162B2 (https=)
BR (1) BR0011994A (https=)
CA (1) CA2370556C (https=)
CO (1) CO5190680A1 (https=)
CZ (1) CZ20014640A3 (https=)
DE (1) DE60011617T2 (https=)
DK (1) DK1194132T3 (https=)
ES (1) ES2222223T3 (https=)
HK (1) HK1043057B (https=)
HU (1) HU227810B1 (https=)
IL (1) IL146928A0 (https=)
MX (1) MXPA01013212A (https=)
NO (1) NO20016283L (https=)
NZ (1) NZ515997A (https=)
PL (1) PL201777B1 (https=)
PT (1) PT1194132E (https=)
SI (1) SI1194132T1 (https=)
SK (1) SK285347B6 (https=)
TR (1) TR200103594T2 (https=)
TW (1) TWI285118B (https=)
WO (1) WO2001000181A2 (https=)
ZA (1) ZA200110005B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
DE60003194T2 (de) * 1999-08-26 2004-06-17 Neurocrine Biosciences, Inc., San Diego Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US7811557B1 (en) * 2000-10-27 2010-10-12 Viacell, Inc. Methods for improving central nervous system functioning
EP2311440A1 (en) * 2001-04-05 2011-04-20 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
KR20030048026A (ko) 2001-07-06 2003-06-18 펜웨스트 파머슈티칼즈 컴파니 옥시모르폰의 서방형 제제
CN1610551A (zh) 2001-07-06 2005-04-27 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的肠胃外给药
JP4417110B2 (ja) * 2001-12-19 2010-02-17 株式会社三和化学研究所 放出制御型成型品
EP1941878A1 (en) * 2002-01-10 2008-07-09 Biovail Laboratories International Srl Sedative non-benzodiazepine formulations
ES2301797T3 (es) * 2002-01-10 2008-07-01 Biovail Laboratories International Srl Formulaciones sedantes no benzodiazepinicas.
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
CA2503121A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
JP4681843B2 (ja) * 2004-09-30 2011-05-11 日本臓器製薬株式会社 固形医薬製剤
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
FR2887455B1 (fr) * 2005-06-28 2007-08-10 Sanofi Aventis Sa Formulation a liberation prolongee de principes actifs de medicaments
AU2006322314A1 (en) * 2005-11-18 2007-06-14 Synthon B.V. Zolpidem tablets
AR056633A1 (es) * 2005-12-07 2007-10-17 Gador Sa Composiciones farmaceuticas de agentes hipnoticos de accion corta en forma de liberacion modificada y los procedimientos para preparar dichas formulaciones
US8309104B2 (en) * 2006-03-02 2012-11-13 Watson Pharmaceuticals, Inc. Oral controlled release formulation for sedative and hypnotic agents
KR20070091960A (ko) * 2006-03-08 2007-09-12 주식회사종근당 졸피뎀 또는 그의 염을 포함하는 안전한 제어방출형 제제조성물
AU2013202441B2 (en) * 2006-04-26 2016-02-25 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
NZ703464A (en) 2006-04-26 2016-05-27 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
JP5275560B2 (ja) * 2006-10-24 2013-08-28 小林化工株式会社 酒石酸ゾルピデム含有素錠の製造方法
EP1938805A1 (en) * 2006-12-22 2008-07-02 LEK Pharmaceuticals D.D. Monolithic sustained release zolpidem tablets
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
WO2009021127A2 (en) * 2007-08-07 2009-02-12 Neurogen Corporation Controlled released compositions
KR101601649B1 (ko) 2008-04-18 2016-03-09 인텍 파마 리미티드 카르비도파／레보도파 위체류 약물 전달
US20100068256A1 (en) 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable medicament release-substance
JP2012510987A (ja) 2008-12-04 2012-05-17 インテック ファーマ リミテッド ザレプロン胃内滞留性薬剤送達システム
RU2384336C1 (ru) * 2009-04-22 2010-03-20 Маргарита Алексеевна Морозова Фармацевтический состав для коррекции психосоматических проявлений
CN102470108A (zh) * 2009-07-07 2012-05-23 桑诺维恩药品公司 非pH依赖型制剂(6-(5-氯-2-吡啶基)-5-[(4-甲基-1-哌嗪基)羰氧基]-7-氧代-6，7-二氢-5H-吡咯并[3，4-b]吡嗪)
FR2949062B1 (fr) * 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
FR2968992B1 (fr) * 2010-12-16 2013-02-08 Sanofi Aventis Comprime pharmaceutique orodispersible a base de zolpidem
TWI505841B (zh) * 2011-09-29 2015-11-01 Taiwan Biotech Co Ltd 治療睡眠障礙之控釋調配物
MY177906A (en) * 2014-02-06 2020-09-25 Sequential Medicine Ltd Composition and method for aiding sleep
RU2659200C1 (ru) * 2017-07-24 2018-06-28 Общество С Ограниченной Ответственностью "Валента - Интеллект" Фармацевтический состав, содержащий алимемазина тартрат

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
GB2185887B (en) * 1987-02-18 1989-12-06 Farmitalia Carlo Erba Ltd Temazepam composition
ES2058546T3 (es) * 1988-09-30 1994-11-01 Rhone Poulenc Rorer Ltd Formulaciones farmaceuticas granulares.
FR2656303B1 (fr) * 1989-12-26 1994-06-10 Parke Davis Solution buvable d'un derive des benzodiazepines et son application pharmacologique.
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
IT1276689B1 (it) * 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
FR2742660B1 (fr) * 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
BR9802915A (pt) * 1997-09-12 2000-01-11 Oscar Gold Procedimento para formar composições farmaceuticas em pilulas ou granulos substancialmente esfericos, de ação controlada e continuada, contendo como agente ativo o (7-bromo-1,3-diidro-5-(2-piridninilo)-2h-1,4-benzodiazep ina-2(1h)-um)
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof

Also Published As

Publication number Publication date
TR200103594T2 (tr) 2002-06-21
TWI285118B (en) 2007-08-11
SK285347B6 (sk) 2006-11-03
WO2001000181A2 (en) 2001-01-04
CN1358087A (zh) 2002-07-10
HU227810B1 (en) 2012-03-28
AU6694400A (en) 2001-01-31
CZ20014640A3 (cs) 2002-03-13
IL146928A0 (en) 2002-08-14
CA2370556C (en) 2009-09-01
PT1194132E (pt) 2004-10-29
PL201777B1 (pl) 2009-05-29
ZA200110005B (en) 2003-02-26
MXPA01013212A (es) 2002-06-21
AU782162B2 (en) 2005-07-07
EP1194132A2 (en) 2002-04-10
PL357348A1 (en) 2004-07-26
DE60011617T2 (de) 2005-06-09
EP1194132B1 (en) 2004-06-16
AR024491A1 (es) 2002-10-02
DK1194132T3 (da) 2004-10-11
CO5190680A1 (es) 2002-08-29
CA2370556A1 (en) 2001-01-04
CN100415216C (zh) 2008-09-03
ATE269062T1 (de) 2004-07-15
SI1194132T1 (en) 2004-10-31
BR0011994A (pt) 2002-03-05
JP2003503340A (ja) 2003-01-28
HUP0201907A3 (en) 2004-05-28
SK19112001A3 (sk) 2002-05-09
NO20016283D0 (no) 2001-12-20
HUP0201907A2 (hu) 2002-12-28
WO2001000181A3 (en) 2001-03-01
ES2222223T3 (es) 2005-02-01
HK1043057A1 (en) 2002-09-06
EP1064937A1 (en) 2001-01-03
NO20016283L (no) 2002-02-27
HK1043057B (en) 2005-02-25
DE60011617D1 (de) 2004-07-22
KR20020015064A (ko) 2002-02-27

Similar Documents

Publication Publication Date Title
NZ515997A (en) Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1242013A4 (en) ORAL TRANSMUCOSAL GALENIC FORM USING SOLID SOLUTION
PL334656A1 (en) Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients
TW429154B (en) A controlled release formulation for poorly soluble basic drugs
HUP0200499A3 (en) Substituted 1-oxo- and 1,3-dioxoisoindolines and their use for preparation of pharmaceutical compositions for reducing inflammatory cytokine levels
SI1509521T1 (sl) 1H-imidazo(4,5-C)kinolinski derivati za zdravljenje od protein kinaze odvisnih bolezni
DE60203461D1 (de) Makrolidcitrat-haltige Formulierungen mit kontrollierter Freisetzung
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
ATE504288T1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
WO2002028376A3 (en) Chrono delivery formulations and method of use thereof
JP2005510485A5 (https=)
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
IL147248A0 (en) Naphthyridine derivatives, process for their preparation, their use and pharmaceutical compositions comprising them
HUP0202686A3 (en) Veterinary formulation for administration of a water-insoluble drug through a water distribution system and process for its preparation
DE60028730D1 (de) Multipartikuläre bisoprolol formulierung
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
PT1558219E (pt) Formulação farmacêutica de olanzapina
IL127129A0 (en) Method of preparation of progesterone tablet for vaginal delivery and tablets so prepared
EE200100539A (et) Prukalopriidi vesilahus suukaudseks manustamiseksning selle valmistamismeetod
CN102049047B (zh) 一种药物组合物
WO2001019357A3 (de) Kombinationspräparat zur behandlung von sexueller dysfunktion
WO2002028405A3 (de) Verfahren zum zyklusstart bei weiblichen zuchttieren
EP1099438A3 (en) Use of APO B secretion/MTP inhibitors
Xu et al. Preparation and in vitro evaluation of gastric floating and sustained-release tablets using Carbopol 971PNF

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 27 JUN 2020 BY CPA GLOBAL

Effective date: 20130517

EXPY Patent expired